- 1 Third doses of COVID-19 vaccines reduce infection and transmission of SARS-CoV-2 and
- 2 could prevent future surges in some populations: a modeling study
- 3 Billy J. Gardner, A. Marm Kilpatrick*
- 5 Department of Ecology and Evolutionary Biology, University of California, Santa Cruz,
- 6 California, USA

8

7 *akilpatr@ucsc.edu

Summary

9

35

- 10 **Background** Vaccines have greatly reduced the impact of COVID-19 globally. Unfortunately,
- evidence indicates that immunity wanes following vaccination, especially with the Delta variant
- 12 (B.1.617.2). Protection against severe disease and death remain high, but protection against
- milder disease and infection have dropped significantly. A third "booster" dose of two-dose
- vaccines has been approved in several countries to individuals at higher risk of severe disease to
- protect those individuals, but the benefit to boosting immunity in younger healthy individuals
- and the effects on transmission are less clear.
- 17 **Methods** Here we use relationships between neutralizing antibody titers and vaccine protection
- against infection and transmission, combined with data on waning and boosting of neutralizing
- antibody titers to examine the impact of a third dose of the Pfizer vaccine on infection and
- transmission and its impact on the pathogen effective reproductive number R_t.
- 21 **Findings** Eight months of waning reduced protection of the Pfizer vaccine against all infections
- 22 from 80.0% (95% CI: 77% to 83%) to 60.4% (95% CI: 53% to 67%); a third dose (which
- increased neutralizing antibody titers 25.9- fold relative to levels after 8 months of waning)
- increased protection to 87.2% (95% CI: 83% to 91%). Increased protection against infection and
- 25 transmission from third doses reduced R_t by 21% to 66% depending on vaccine coverage and
- previous infection and reduced R_t below 1 when vaccination coverage was high or contact rates
- were well below pre-pandemic levels.
- 28 Interpretation A third dose of the Pfizer vaccine could reduce transmission of SARS-CoV-2,
- 29 which would reduce infection in unvaccinated individuals and breakthrough infections in
- vaccinated individuals. While vaccination of unvaccinated individuals, especially in developing
- 31 countries, would be more effective for reducing disease than providing a third dose to vaccinated
- individuals, the benefit of a third dose in reducing transmission is sizeable and increases with
- vaccine coverage and contact rates among individuals.
- Funding California Department of Health, National Science Foundation

Introduction

- The emergence of the Delta variant (B.1.617.2) of SARS-CoV-2 has caused a surge of infections globally, even in populations with high vaccination coverage [1, 2]. This is due, in part, to the much higher infectiousness of this virus variant [2, 3], moderate immune evasion [4-6], and, increasingly, waning vaccine immunity, based on both levels of neutralizing antibodies [7-10] and studies of vaccine effectiveness [11-13]. Several countries have recently offered third doses to individuals at higher risk of severe disease [14] because protection for these individuals, even against severe disease, has waned the most [11]. However, protection against severe disease for heathy individuals has waned far less and the need and benefit of providing third doses for young healthy individuals has been questioned [15]. Many populations, especially those in Africa, have received very few vaccine doses and many have argued that vaccinating these populations would provide a larger public health benefit than providing third doses to already vaccinated individuals [15] and for reducing the evolutionary potential of the virus [16].
- While the direct benefit of providing third doses to elderly and other at-risk individuals is now clear [17], the indirect benefit for reducing transmission of SARS-CoV-2 is poorly understood. Most studies examining waning of vaccine effectiveness over time have focused on protection against symptomatic disease [11-13]. The impact of waning immunity and boosting on vaccine protection against all infections (symptomatic and asymptomatic) and against virus transmission has been mentioned [15], but not quantified, despite its potential importance for reducing infection in unvaccinated individuals and breakthrough infections in vaccinated individuals.
 - Here we extend a previous approach that showed strong correlations between a measure of immunity, neutralizing antibody titers and vaccine protection [18]. This study examined protection against symptomatic disease against non-Delta variants using data from randomized control trials [18]. We extend this approach by mapping neutralizing antibody titers to protection against both symptomatic disease and all infections for both Delta and non-Delta variants. We then use measurements of waning neutralizing antibody titers and boosting with a third dose to estimate the impact on protection against all infections, and the reproductive number of the virus, Rt which quantifies the average number of cases that each case goes on to infect.

Methods

Protection against infection, disease, and transmission

We collected data from the literature (including ongoing systematic reviews: [19, 20]) on protective efficacy and effectiveness of vaccines and convalescent sera for SARS-CoV-2 and categorized each study by variant type (Delta and non-Delta; estimates of protection against the Beta variant were excluded) and endpoint (symptomatic infections and all infections) (Table S1). We excluded studies of protection where the endpoint was "any infection" because these studies do not capture all infections; they include an unknown fraction of the asymptomatic infections. We also obtained an estimate of vaccine effectiveness against transmission (given infection) for Astrazeneca (ChAdOx1) and Pfizer-BioNTech (BNT162b2) for the Delta variant [21]. This study quantified secondary attack rates using qPCR tests of contacts that were

symptomatic or tested positive using lateral flow tests [21], but likely missed some asymptomatic or mildly symptomatic infected contacts, and thus provides a crude estimate of protection. We gathered neutralizing antibody titer data for each vaccine and ratios of titers to convalescent sera from [18]. Finally, we estimated the ratio of neutralizing antibody titers to the Delta variant relative to earlier variants (Table S2), and used these to adjust neutralizing antibody titer ratio estimates in analyses with vaccine effectiveness or protection from previous infection against the Delta variant (Table S1).

Estimating neutralizing antibody titers after waning and third doses

We obtained data on neutralizing antibody titers following vaccination for the Pfizer-BioNTech vaccine at several time points between 1 month after the second dose and 8 months post second dose, as well as 1 month after a third dose [10, 22]. One of these studies [22] reported data for two age groups separately (18-55 and 65+), so we weighted these estimates by the fraction of individuals in the age groups 18-60 and 60+ in the United States (71.0% and 29.0%), which is similar to the age distribution in the European Union [23]. We fit these data to a 3-parameter exponentially decaying function ($y = c_0e^{c_1*t} + c_2$) to estimate the neutralizing antibody titer on any day, t, post vaccination (Figure 2; Table S4). We also fit similar relationships to data on neutralizing antibody titers over time for the Moderna vaccine [9], and following infection with SARS-CoV-2 [7] (starting when titers peak at 25 days post symptom onset [24]) (Figure 2; Table S4). Rates of waning for hybrid immunity following infection and vaccination with Pfizer-BioNtech and Moderna vaccines combined were statistically similar to rates of waning following vaccination with Pfizer-BioNtech [8], so we used the same relative rates of waning as for Pfizer-BioNtech (Figure 2; Table S4) but adjusted titers for the 7.9-fold higher initial level in those with hybrid immunity [8]. We assumed that boosting individuals that had been infected and then vaccinated resulted in similar neutralizing antibody titers as people that had been vaccinated but not previously infected, because after 6 months of waning post-vaccination, these individuals with hybrid immunity had neutralizing antibody titers that had fallen below levels for newly vaccinated individuals [8].

Linking protection against infection and disease with neutralizing antibody titers

We modeled the relationship between protection from SARS-CoV-2 infections or disease and the ratio of neutralizing antibody titers relative to convalescent sera using logistic regression, following a previous approach [18]. In this analysis each data point is a single study of protection against SARS-CoV-2 infection or disease for a single virus variant. We included an interaction between neutralizing antibody titers and variant-endpoint to estimate separate relationships for each of four variant-endpoints (pairwise combinations of Delta and non-Delta, symptomatic disease, and all infections). We used the separate relationship for the Delta – all infections endpoint for all analyses described below.

The raw data for each estimate of protection (vaccine efficacy, vaccine effectiveness, or protection from previous infection) were unavailable, so we determined the effective sample sizes for a sample from a binomial distribution that matched the confidence intervals of the protection estimates (Table S1). We used the fitted model (Figure 1) to estimate protection against all infections for the Delta variant from Pfizer - BioNTech vaccination using neutralizing

- antibody titers measured after eight months of waning and titers measured after a 3rd dose [22].
- We performed a similar analysis using the limited data available to link neutralizing antibody
- titers to protection against transmission given infection [21] (Figure S1).
- 128 The impact of a third dose on the reproductive number, R_t

129

130

131

132

133134

135

136

137

138

139 140

141

142143

144

145

146

147148

149150

151

152

153

154

155156

157

158 159 160

161162

163

164

165

166

167168

169

We used patterns of waning and boosting of neutralizing antibody titers and the relationships between neutralizing antibody titers and protection against all infections and transmission to estimate the impact of providing a third dose of the Pfizer – BioNTech vaccine to increasing fractions of vaccinated individuals on the reproductive number of SARS-CoV-2, Rt. The effective reproductive number, R_t, is the average number of secondary cases that each case infects. It is equal to the basic reproductive number for a fully susceptible population, R₀, multiplied by the fraction of the population that is still susceptible. We split the population based on vaccination and infection to determine the effective fraction susceptible: fraction previously infected and unvaccinated, fpu, fraction previously infected and vaccinated, fpv; fraction unvaccinated, fu, fraction vaccinated (with two doses of either Pfizer-BioNtech or Moderna), fv, and fraction boosted with a third dose, f_B (f_U+f_V+f_B=1). We estimated the susceptibility of each group using estimates of the protection against infection, VE_I, (Figure 1) and the reduced probability of transmitting given infection, VE_T, (Figure S1) for each group using the subscripts above, except VE_{IH} and VE_{TH} which are estimates of protection from hybrid immunity from infection and vaccination. We used these estimates of protection to calculate R_t for five groups of people: fully susceptible unvaccinated (1-f_P)f_U, previously infected unvaccinated f_Pf_U, previously uninfected vaccinated (1-f_P)f_V, previously infected vaccinated f_Pf_V, and previously uninfected vaccinated and boosted with a third dose (1-f_P)f_B:

```
R_{t} = R_{0} \left[ \ (1-f_{PU})f_{U} + f_{PU}f_{U}(1-VE_{IP})(1-VE_{TP}) + (1-f_{PV})f_{V}(1-VE_{IV})(1-VE_{TV}) + \ (f_{PV}f_{V})(1-VE_{IH})(1-VE_{IH}) + (f_{B})(1-VE_{IB}) \ (1-VE_{IB}) \ (1-VE_{I
```

We examined the effect of boosting vaccinated individuals with a third dose by considering five scenarios that differ in contact rates/ R_0 ($R_0 = 3.7$ or 7 reflecting mid-summer 2021 levels in the USA and pre-pandemic behavior, respectively), vaccination coverage (56% similar to USA in mid-October [23]; 60%, 75% and 100%), and the fraction of the population previously infected (0.5%, 28.2% and 56.4%, with the last value being similar to estimates of the fraction of the USA population that had been infected by mid-October, based on 44 million cases and an infection to case ratio of 4.2 [25]). The scenarios and rationale were (Table S5):

- 1) R0 = 3.7, 56% vaccinated, 56.4% previously infected: approximates USA population in mid-October with contact rates similar to summer 2021, as might occur in winter 2021
- 2) R0 = 3.7, 60% vaccinated, 0.5% previously infected: approximates countries/populations that effectively suppressed transmission and haven't yet reached high vaccination levels and have somewhat reduced contact rates (e.g. New Zealand, Australia, Hong Kong, etc.)
- 3) R0 = 3.7,75% vaccinated, 28.2% previously infected: approximates some populations with higher vaccination and lower fraction infected than scenario (1) (e.g. California)
- 4) R0 = 7, 100% vaccinated, 56.4% previously infected: a hypothetical optimistic scenario to compare to scenario (1) to determine if vaccination with or without boosting could limit transmission if behavior returns to pre-pandemic levels

5) R0 = 7, 56% vaccinated, 56.4% previously infected: a more realistic optimistic scenario to compare to scenario (1) to determine if boosting could limit transmission if behavior returns to pre-pandemic levels

For all scenarios we estimated the waning of vaccine-derived immunity as of October 15, 2021 using the timing of vaccination in the USA [26]; Figure S2) and patterns of waning neutralizing antibody titers over time for Pfizer-BioNtech and Moderna vaccines or hybrid immunity (Figure 2). We estimated the waning of infection-derived immunity as of October 15, 2021 using the timing of deaths in the USA [23] shifted by 24 days [27] (Figure S3) and the rate of waning of infection-derived immunity (Figure 2). We estimated the number of infections in vaccinated and unvaccinated people using the ratios of cases in these two groups over time [28] (Figure S4). We used these data on the timing of vaccination and infection and rates of antibody waning to determine the protection against infection and transmission as of October 15, 2021 (Table S6). We calculated 95% CIs for predicted values of R_t that incorporated uncertainty in the relationships between neutralizing antibody titers and protection against infection and transmission (Figures 1 and S4). We drew 10,000 samples from a uniform distribution c(0,1) and used these as quantiles for a normal distribution to generate draws (on a logit scale) for values of protection VE for each value of neutralizing antibody titer adjusted for waning for the fraction of the population that was vaccinated or infected at each day in the past. This approach essentially drew a single line from the 95% CI of lines in Figure 1 and used that for all levels of waning. We then inverse-logit transformed these values of VE and used them to generate 10,000 values of R_t for that scenario. We took the 2.5% and 97.5% quantiles to estimate the 95% confidence intervals (CIs) for R_t for each point of each scenario.

Results

170

171

172173

174

175

176

177

178

179180

181

182

183

184

185

186

187

188 189

190

191

192193

- 195 There were strong relationships between the ratio of neutralizing antibody titers to convalescent
- sera and protection against both symptomatic infection and all infections (Figure 1; Table S3).
- 197 Protection was highest for symptomatic disease for non-Delta variants and lower for protection
- against all infections for both non-Delta and Delta variants (Figure 1; Table S3).
- Neutralizing antibodies generated by vaccination with the Pfizer-BioNtech vaccine wane 8.06-
- fold after 8 months (Figure 1), with most of this waning occurring in the first 3 months (Figure
- 201 2). The strong relationship between protection and neutralizing antibody titers (Figure 1; Table
- S3) suggests that this waning of neutralizing antibody titers will reduce protection against all
- 203 infections for the Delta variant from 80.0% (95% CI: 77.0% to 83.0%) to 60.4% (95% CI: 53.3%
- to 67.2%) (Figure 1, red line, compare points labelled "Pfizer 1 week" to "Pfizer 8 mo waning";
- Figure 2 purple point). Similarly, this waning reduced the protection against transmission given
- 206 infection from 38% (95% CI: 28% to 47%) to 10.5% (95% CI: 6.6% to 16.4%) (Figure S4). A
- third dose of the Pfizer-BioNtech vaccine boosted antibody titers 25.9-fold relative to levels after
- 8 months of waning, or 25.9/8.06 = 3.22 higher than one week after dose 2 [22]. The fitted
- 209 relationship (Figure 1; Table S3) suggests a third dose of the Pfizer-BioNtech vaccine would
- increase protection against infection from an eight-month waned value of 60.4% (95% CI: 53.3%
- 211 to 67.2%) to a boosted value of 87.2% (95% CI: 82.8% to 90.7%) and would boost protection
- against transmission given infection from 10.5% to 60.7% (95% CI: 42.3% to 76.5%) (Figure
- 213 S1).




Fig. 1. Protection against symptomatic infections or all infections plotted against the ratio of neutralizing antibody titers relative to convalescent sera. Each point represents a single estimate of vaccine efficacy for a single vaccine & virus variant (from randomized control trials) or vaccine effectiveness (from observational studies) or an estimate of protection from previous infection from observational studies. Colors show the SARS-CoV-2 variant (Delta or non-Delta) and endpoint of the study (symptomatic infections or all infections). Closed symbols and 95% CIs show aggregated data for each vaccine-variant-endpoint. Open symbols show estimates from individual studies if there were more than one estimate for a vaccine-variant-endpoint. Points have been jittered along the x-axis to facilitate presentation; all points for the same vaccine-variant have the same x-value. Lines show a fitted logistic regression with protection as the response and an interaction between and neutralizing antibody ratio and variant-endpoint as predictors (Table S3). The lower panel shows relationships for the Delta variant, with all points shifted 2.88-fold lower along the x-axis to reflect the lower neutralizing antibodies observed with this variant across studies (Table S2).

Neutralizing antibody titers waned for both vaccine-derived immunity (Pfizer-BioNtech and Moderna vaccines) and infection derived immunity (Figure 2A, B). Rates of waning were fastest for the Pfizer-BioNtech vaccine, followed by infection-generated antibodies, whereas antibodies from the Moderna vaccine waned the slowest (Figure 2B; Table S4). Antibodies from infection stabilized at a slightly higher level relative to their peak than either vaccine (Figure 2B), but starting antibodies were lowest for infection, followed by Pfizer-BioNtech and then Moderna (Figure 2A).

We used the relationship between neutralizing antibody titers and protection against infection for the Delta variant (Figure 1; Table S3), and patterns of waning of antibody titers

(Figure 2A, B) to estimate the waning of protection against all infections over time (Figure 2C). Earlier work suggested that antibodies from infection followed by vaccination ("hybrid immunity") were 7.9-fold higher than for Pfizer-BioNtech vaccination and waned at a similar rate as Pfizer-BioNtech [8], so we used the same Pfizer-BioNtech neutralizing antibody decay curve, but adjusted for the much higher initial peak. Protection against all infections was highest for Hybrid immunity, followed by Moderna, Pfizer and then infection-derived immunity. The relatively fast and sustained waning rate of neutralizing antibodies for the Pfizer-BioNtech vaccine suggests that protection from this vaccine was initially higher than infection-derived immunity but the two were similar after four months (Figure 2C).




Figure 2. Waning of neutralizing antibodies and protection against infection over time. A) Neutralizing antibody titers relative to convalescent sera, adjusted for lower neutralization titers with the Delta variant. B) The same data as in panel (A) but rescaled to be relative to the peak initial value so rates of waning and levels of stabilization can be visualized and analyzed simultaneously (Table S4). C) Protection against infection over time using the patters of waning in Figure 2A and the relationships between antibody titers and protection against infection (Figure 1 red line).

Boosting immunity, by providing a third dose of the Pfizer-BioNtech to all doubly vaccinated individuals in the USA (56% of the total population), could reduce the reproductive number R_t by 22% from 1.26 to 0.98 and stop a surge (Figure 3, red line), assuming current levels of vaccination coverage (56%), estimated immunity from previous infection (56.4%), and behavior consistent with the summer Delta surge (R_0 =3.7) (see Methods for further details). Unfortunately, in places where vaccination is slightly higher (60%), but previous infection is much lower, (0.5%; e.g. New Zealand), boosting with a third dose would be unable to prevent a surge with the same contact rates (Figure 3, grey line). Conversely, in populations where vaccination is higher (75%) and previously infection is lower (28.2%) (e.g. California), boosting at least 45% of the population (60% of those vaccinated) could push R_t below 1 (Figure 3 blue line).

If contact rates return to pre-pandemic levels (R_0 =7), with mid-October USA vaccine coverage (56%) and infection history (56.4%), then boosting could reduce R_t by a larger absolute amount (but the same relative amount, 21%) than with lower contact rates, from 2.37 to 1.85 (Figure 3, green line) but cases would still rise rapidly because 1.85 is still far above 1. Using the same number of 3^{rd} doses to doubly vaccinate unvaccinated individuals would be more impactful, and could reduce R_t to 1.49 (Figure 3, compare right end of green line to black point labelled 84% vaccinated on left side). If contact rates return to pre-pandemic levels (R_0 =7), then even if a population had 100% vaccination coverage and 56.4% previously infected, waning of vaccine and infection-derived immunity would cause cases to continue to grow without boosting (Figure 3, left end of yellow line: R_t =1.17 which is greater than 1; without waning R_t would be 0.74, well below 1). However, boosting >21% of a fully (100%) vaccinated population could prevent a surge in cases, even with pre-pandemic behavior (Figure 3, yellow line).




Figure 3. Relationship between third dose coverage and the pathogen effective reproductive number, R_t . Lines and 95% CIs show the estimated reproductive number for five scenarios (see Methods). The single black point shows the impact of using all third doses from the right end of the green line to doubly-vaccinate unvaccinated individuals, which would bring the vaccination coverage from 56% to 84%. Protection from vaccination and previous infection for all lines reflect waning, as described in the text (Table S3). The dashed horizontal line shows the threshold reproductive number $R_t = 1$, separating a

Discussion

289

290

291

- Vaccines have greatly reduced the impact of COVID-19 globally, but waning immunity and the
- 293 emergence of the Delta variant have led to surges in cases despite high vaccination coverage in
- 294 many populations [1, 7-10]. This has led to many countries recommending third doses to boost
- immunity to protect at-risk individuals [14]. However, the impact of third doses on transmission
- of SARS-CoV-2 has received far less attention [15].

growing from a shrinking epidemic.

- We found that a third dose could substantially reduce transmission, especially in highly
- vaccinated populations, and the effect was larger in populations with lower acquired immunity
- from infection and when contact rates (which scale R_0) were higher. We showed that neutralizing
- antibodies are strongly correlated not just with protection against symptomatic disease [4, 18],
- but also with protection against all infection and transmission given infection (Figures 1, S4).
- This allowed us to estimate the effect of waning and boosting on transmission, and the pathogen
- reproductive number R_t. Boosting immunity by providing a third dose to individuals vaccinated
- more than three months ago (after most waning has occurred: Figure 2) could reduce
- transmission substantially and could prevent a winter surge in many populations where
- vaccination coverage is high, as long as contact rates and behavior don't fully return to pre-
- pandemic levels. In contrast, with pre-pandemic contact rates, only very high levels of vaccine
- 308 coverage, and a combination of a moderate level of previous infection and boosting could
- 309 prevent a surge.
- We also found that despite the substantial potential impact of boosting on transmission,
- deploying vaccine doses to unvaccinated individuals has a larger effect on transmission (Figure
- 312 3, compare the black point to the right end of the green line). In addition, the direct effect of
- vaccinating unvaccinated people is much larger than the benefit of providing a third dose for
- severe disease and death since protection against severe disease has only waned slightly, except
- in older or at-risk individuals [11]. Unfortunately, vaccine hesitancy among those not vaccinated
- is quite high in many populations (e.g., USA, Russia, etc.) and many people are unwilling to get
- vaccinated despite strong incentives, often due to misinformation [29-31], making it difficult to
- 318 increase vaccine coverage in some populations. In contrast, there other populations where
- vaccine coverage is very low, primarily due to poor availability, especially in Africa [32].
- 320 Clearly, limited vaccine doses would be most effectively used in these populations and should be
- deployed there until supplies are no longer limiting.

Our study has several limitations. First and foremost is the reliance on neutralizing antibody 322 323 titers as a predictor of protection against infection and transmission. Although the analyses here, 324 and elsewhere suggest a strong relationship between neutralizing antibody titers and protection at the population level [4, 18] and individual level [33], other parts of the immune system, such as 325 T-cells, also play key roles in protection, especially against severe disease. Second, our analyses 326 327 use population averages for estimates of protection against infection and transmission and ignore age-specific variation among individuals (as well as other factors). Third, the data available to 328 estimate vaccine protection against all infections and against transmission given infection from 329 the Delta variant was limited. Fourth, it's unclear how long antibody titers will be elevated 330 following a third dose, so the effect of boosting might not be long lasting. Finally, we assume 331 well-mixed populations in calculating reductions in the reproductive number R_t . Clearly a 332 targeted vaccination approach would be more effective than that outlined here if individuals that 333 334 were highly connected to at-risk individuals could be targeted for third doses [34]. Finally, we focused on third dose boosters using the Pfizer vaccine, but third doses for other vaccines, 335 including heterologous boosting [35], have also recently been approved in the USA and 336 elsewhere. 337 In summary, many countries have already begun to deploy third doses to protect at-risk 338 individuals, and some countries (e.g. Israel, [17]) have even deployed third doses to the general 339 population to reduce transmission. However, uptake in most countries has been low, criteria for 340 third doses are still vague [14], and only moderate effort has been deployed to deploy third doses 341 widely. Our results suggest that widespread boosting of the general population could 342 substantially reduce transmission. Polls in some countries suggest a large fraction of the 343 vaccinated population would be willing to get a third dose (e.g., 76% of Americans; [36]). If 344 vaccine doses for providing initial doses to populations with very low coverage are not limiting. 345 346 then offering third doses to the general public could play a significant role in reducing transmission. This would directly protect boosted individuals [37], indirectly protect 347 unvaccinated and vaccinated individuals, and reduce the possibilities for viral evolution [16]. 348 349 **Contributors** 350 AMK conceived the study. BJG and AMK performed the analyses and wrote the paper. 351 352 **Declaration of interests** 353 All authors declare no competing interests. **Data sharing** 354 Code and data files to replicate the figures and analyses of this paper can be found at: 355 https://github.com/marmkilpatrick/Vaccine-boosters 356 Acknowledgements 357 We thank the Kilpatrick lab for helpful comments. 358

References

- 360 1. Wadman M. Israel's grim warning: Delta can overwhelm shots. Science.
- 361 2021;373(6557):838-9.
- 2. Elliott P, Haw D, Wang H, Eales O, Walters CE, Ainslie KEC, et al. Exponential growth,
- 363 high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant.
- 364 Science. 0(0):eabl9551. doi: doi:10.1126/science.abl9551.
- 365 3. Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al.
- Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021.
- 367 Eurosury. 2021;26(24):2100509.
- 368 4. van Gils MJ, Lavell AHA, van der Straten K, Appelman B, Bontjer I, Poniman M, et al.
- 369 Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-
- 370 CoV-2 variants. medRxiv. 2021:2021.09.27.21264163. doi: 10.1101/2021.09.27.21264163.
- 5. Davis C, Logan N, Tyson G, Orton R, Harvey W, Haughney J, et al. Reduced
- neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination.
- 373 medRxiv. 2021:2021.06.23.21259327. doi: 10.1101/2021.06.23.21259327.
- 6. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al.
- 375 Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature.
- 376 2021;596(7871):276-80.
- 377 7. Havervall S, Marking U, Gordon M, Ng H, Greilert-Norin N, Lindbo S, et al.
- Neutralization of VOCs including Delta one year post COVID-19 or vaccine. medRxiv.
- 379 2021:2021.08.12.21261951. doi: 10.1101/2021.08.12.21261951.
- 380 8. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al.
- mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern.
- 382 Science. 2021:eabm0829.
- Doria-Rose N, Suthar MS, Makowski M, O'Connell S, McDermott AB, Flach B, et al.
- Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-
- 385 19. N Engl J Med. 2021;384(23):2259-61.
- 10. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune
- 387 humoral response to BNT162b2 covid-19 vaccine over 6 months. New England Journal of
- 388 Medicine. 2021.
- 389 11. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Vaccine
- 390 effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and
- severe COVID-19 in the UK. medRxiv. 2021.
- 392 12. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Haas E, et al.
- Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel. medRxiv. 2021.
- 13. Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al.
- Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J
- 396 Med. 2021.
- 397 14. Furlong A, Deutsch J. A country-by-country guide to coronavirus vaccine booster plans
- 398 2021. Available from: https://www.politico.eu/article/vaccine-booster-coronavirus-covid-19-
- 399 europe-delta-varian-who/.
- 400 15. Krause PR, Fleming TR, Peto R, Longini IM, Figueroa JP, Sterne JAC, et al.
- 401 Considerations in boosting COVID-19 vaccine immune responses. Lancet (London, England).
- 402 2021;398(10308):1377-80. doi: 10.1016/S0140-6736(21)02046-8. PubMed PMID: 34534516.
- 403 16. Wagner CE, Saad-Roy CM, Morris SE, Baker RE, Mina MJ, Farrar J, et al. Vaccine
- 404 nationalism and the dynamics and control of SARS-CoV-2. medRxiv. 2021.

- 405 17. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al.
- 406 Protection of BNT162b2 vaccine booster against covid-19 in Israel. N Engl J Med.
- 407 2021;385(15):1393-400.
- 408 18. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al.
- 409 Neutralizing antibody levels are highly predictive of immune protection from symptomatic
- 410 SARS-CoV-2 infection. Nat Med. 2021:1-7.
- 411 19. Higdon MM, Wahl B, Jones CB, Rosen JG, Truelove SA, Baidya A, et al. A systematic
- 412 review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and
- disease. medRxiv. 2021:2021.09.17.21263549. doi: 10.1101/2021.09.17.21263549.
- 414 20. WHO. Results of COVID-19 Vaccine Effectiveness Studies: An Ongoing Systematic
- 415 Review 2021. Available from: https://view-hub.org/sites/default/files/2021-
- 416 <u>09/COVID19%20VE%20Studies_Forest%20Plots_1.pdf.</u>
- 417 21. Eyre DW, Taylor D, Purver M, Chapman D, Fowler T, Pouwels KB, et al. The impact of
- 418 SARS-CoV-2 vaccination on Alpha and Delta variant transmission. medRxiv.
- 419 2021:2021.09.28.21264260. doi: 10.1101/2021.09.28.21264260.
- 420 22. Falsey AR, Frenck Jr RW, Walsh EE, Kitchin N, Absalon J, Gurtman A, et al. SARS-
- 421 CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. N Engl J Med. 2021.
- 422 23. CDC. COVID Data Tracker 2021. Available from: https://covid.cdc.gov/covid-data-
- 423 tracker/#vaccinations_vacc-total-admin-rate-total.
- 424 24. Arkhipova-Jenkins I, Helfand M, Armstrong C, Gean E, Anderson J, Paynter RA, et al.
- 425 Antibody response after SARS-CoV-2 infection and implications for immunity: a rapid living
- review. Ann Intern Med. 2021;174(6):811-21. doi: doi.org/10.7326/M20-7547.
- 427 25. CDC. Estimated COVID-19 Burden 2021. Available from:
- 428 https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html.
- 429 26. CDC. COVID-19 Vaccinations in the United States 2021. Available from:
- 430 https://covid.cdc.gov/covid-data-tracker/#vaccinations vacc-total-admin-rate-total.
- 431 27. Lewnard JA, Liu VX, Jackson ML, Schmidt MA, Jewell BL, Flores JP, et al. Incidence,
- 432 clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California
- and Washington: prospective cohort study. BMJ-British Medical Journal. 2020;369:10. doi:
- 434 10.1136/bmj.m1923. PubMed PMID: WOS:000538336800001.
- 435 28. CDC. Rates of COVID-19 Cases and Deaths by Vaccination Status 2021. Available
- 436 from: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status.
- 437 29. Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigron A, et al. Vaccine
- hesitancy: the next challenge in the fight against COVID-19. Eur J Epidemiol. 2020;35(8):775-9.
- 439 30. Sallam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of
- vaccine acceptance rates. Vaccines. 2021;9(2):160.
- 441 31. Machingaidze S, Wiysonge CS. Understanding COVID-19 vaccine hesitancy. Nat Med.
- 442 2021;27(8):1338-9.
- 443 32. Acharya KP, Ghimire TR, Subramanya SH. Access to and equitable distribution of
- 444 COVID-19 vaccine in low-income countries. npj Vaccines. 2021;6(1):1-3.
- 445 33. Gilbert PB, Montefiori DC, McDermott A, Fong Y, Benkeser D, Deng W, et al. Immune
- 446 Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. medRxiv.
- 447 2021:2021.08.09.21261290. doi: 10.1101/2021.08.09.21261290.
- 448 34. Firth JA, Hellewell J, Klepac P, Kissler S, Kucharski AJ, Spurgin LG. Using a real-world
- network to model localized COVID-19 control strategies. Nat Med. 2020;26(10):1616-22.

- 450 35. Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, et al.
- 451 Heterologous SARS-CoV-2 Booster Vaccinations Preliminary Report. medRxiv.
- 452 2021:2021.10.10.21264827. doi: 10.1101/2021.10.10.21264827.
- 453 36. Aboulenein A, Kahn C. Most vaccinated Americans want COVID-19 booster shots -
- Reuters/Ipsos poll: Reuters; 2021. Available from: https://www.reuters.com/business/healthcare-
- 455 pharmaceuticals/most-vaccinated-americans-want-covid-19-booster-shots-reutersipsos-poll-
- 456 2021-09-01/.
- 457 37. Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of
- a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in
- 459 Israel: an observational study. The Lancet. 2021.
- 460 38. Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. Effectiveness
- of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection
- and severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ.
- 463 2021;374:n1943. doi: 10.1136/bmj.n1943.
- 464 39. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA
- Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412-
- 466 23.
- 467 40. Emary KR, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al. Efficacy of
- 468 ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.
- 469 1.1. 7): an exploratory analysis of a randomised controlled trial. The Lancet.
- 470 2021;397(10282):1351-62.
- 471 41. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine
- coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine
- against infection (SIREN): a prospective, multicentre, cohort study. The Lancet.
- 474 2021;397(10286):1725-35.
- 475 42. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al.
- 476 Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant. N Engl J Med.
- 477 2021:585-94.
- 478 43. Martínez-Baz I, Miqueleiz A, Casado I, Navascués A, Trobajo-Sanmartín C, Burgui C, et
- al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and
- 480 hospitalisation, Navarre, Spain, January to April 2021. Eurosurv. 2021;26(21):2100438.
- 481 44. Narrainen F, Shakeshaft M, Asad H, Holborow A, Blyth I, Healy B. The protective effect
- 482 of previous COVID-19 infection in a high-prevalence hospital setting. Clinical Medicine.
- 483 2021;21(5):e470.
- 484 45. Nasreen S, He S, Chung H, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of
- 485 COVID-19 vaccines against variants of concern, Canada. Medrxiv. 2021.
- 486 46. Pouwels KB, Pritchard E, Matthews P, Stoesser NB, Eyre DW, Vihta K-D, et al. Impact
- of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the
- 488 UK. medRxiv. 2021.
- 489 47. Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta K-D, et al. Impact of
- 490 vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat Med. 2021:1-9.
- 491 48. Satwik R, Satwik A, Katoch S, Saluja S. ChAdOx1 nCoV-19 effectiveness during an
- unprecedented surge in SARS COV-2 infections. European Journal of Internal Medicine. 2021.
- 49. Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane F, Al Khatib HA, et al.
- 494 BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B. 1.617. 2)
- variant in Qatar. MedRxiv. 2021.

- 496 50. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-
- dose administration and the influence of the timing of the booster dose on immunogenicity and
- efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
- 499 The Lancet. 2021;397(10277):881-91.
- 500 51. Whitaker H, Tsang R, Byford R, Andrews N, Sherlock J, Pillai P. Pfizer-BioNTech and
- Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups. Khub net Posted July. 2021.
- 503 52. Richardson JR, Goetz R, Mayr V, Lohse MJ, Holthoff H-P, Ungerer M. SARS-COV2
- mutant-specific T cells and neutralizing antibodies after vaccination and up to 1 year after
- infection. medRxiv. 2021.

513

514

- 506 53. Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Neutralising antibody
- activity against SARS-CoV-2 VOCs B. 1.617. 2 and B. 1.351 by BNT162b2 vaccination. The
- 508 Lancet. 2021;397(10292):2331-3.
- 509 54. Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Ability of AZD1222
- vaccination to elicit neutralising antibodies against SARS-CoV-2 VOC B. 1.617. 2 (Delta).
- 511 Lancet (London, England). 2021;398(10296):207.

Supplemental Tables and Figures

- Table S1. Data and studies used to estimate the relationship between protection (VE)
- against infection, disease and transmission endpoints and neutralizing antibody titer (NAT)
- ratios relative to convalescent sera (Figure 1). A single value of the neutralizing antibody
- 518 titer ratio was used for each vaccine and variant; values for the Delta variant are 2.88-fold
- lower than for non-Delta variants (Table S2). N_{eff} are the effective sample sizes used for the
- 520 logistic regression (Table S3).

| Study | Vaccine or | Variant | Endpoint | NAT Ratio | VE (95% CI) | Neff |
|-------|--------------|-----------|----------------|-----------|------------------|------|
| | Convalescent | | | | | |
| [13] | Moderna | non-Delta | Symptomatic | 4.13 | 0.99 (0.92-1.00) | 70 |
| [38] | Moderna | non-Delta | Symptomatic | 4.13 | 0.94 (0.86-0.97) | 112 |
| [38] | Pfizer | non-Delta | Symptomatic | 2.37 | 0.91 (0.88-0.93) | 550 |
| [39] | Pfizer | non-Delta | Symptomatic | 2.37 | 0.94 (0.87-0.98) | 96 |
| [40] | Astrazeneca | non-Delta | Symptomatic | 0.54 | 0.75 (0.42-0.89) | 16 |
| [21] | Astrazeneca | Delta | Transmission | 0.19 | 0.16 (0.12-0.21) | 243 |
| [21] | Pfizer | Delta | Transmission | 0.82 | 0.38 (0.28-0.47) | 109 |
| [41] | Convalescent | non-Delta | All infections | 1 | 0.83 (0.76-0.87) | 168 |
| [41] | Pfizer | non-Delta | All infections | 2.37 | 0.86 (0.76-0.97) | 49 |
| [18] | Astrazeneca | non-Delta | Symptomatic | 0.54 | 0.62 (0.41-0.76) | 34 |
| [18] | Convalescent | non-Delta | Symptomatic | 1 | 0.89 (0.66-0.98) | 18 |
| [18] | CoronaVac | non-Delta | Symptomatic | 0.17 | 0.50 (0.36-0.62) | 60 |
| [18] | JJ | non-Delta | Symptomatic | 0.47 | 0.67 (0.59-0.74) | 147 |
| [18] | Moderna | non-Delta | Symptomatic | 4.13 | 0.94 (0.89-0.97) | 150 |
| [18] | Novavac | non-Delta | Symptomatic | 3.97 | 0.96 (0.68-0.99) | 25 |

| 54.07 | 1 – ~ | | ~ . | | | |
|-------|--------------|-----------|----------------|------|------------------|------|
| [18] | Pfizer | non-Delta | Symptomatic | 2.37 | 0.95 (0.90-0.98) | 200 |
| [18] | Sputnik | non-Delta | Symptomatic | 1.41 | 0.92 (0.85-0.95) | 140 |
| [42] | Astrazeneca | Delta | Symptomatic | 0.19 | 0.67 (0.61-0.72) | 330 |
| [42] | Astrazeneca | non-Delta | Symptomatic | 0.54 | 0.75 (0.68-0.79) | 240 |
| [42] | Pfizer | Delta | Symptomatic | 0.82 | 0.88 (0.85-0.90) | 750 |
| [42] | Pfizer | non-Delta | Symptomatic | 2.37 | 0.94 (0.92-0.95) | 720 |
| [43] | Pfizer | non-Delta | Symptomatic | 2.37 | 0.82 (0.73-0.88) | 110 |
| [44] | Convalescent | non-Delta | All infections | 1 | 0.97 (0.81-1.00) | 25 |
| [45] | Astrazeneca | non-Delta | Symptomatic | 0.54 | 0.91 (0.62-0.98) | 22 |
| [45] | Astrazeneca | Delta | Symptomatic | 0.19 | 0.87 (0.69-0.95) | 32 |
| [45] | Moderna | non-Delta | Symptomatic | 4.13 | 0.92 (0.88-0.95) | 225 |
| [45] | Moderna | non-Delta | Symptomatic | 4.13 | 0.96 (0.85-0.99) | 50 |
| [45] | Moderna | Delta | Symptomatic | 1.44 | 0.95 (0.91-0.97) | 220 |
| [45] | Pfizer | non-Delta | Symptomatic | 2.37 | 0.89 (0.86-0.91) | 1440 |
| [45] | Pfizer | Delta | Symptomatic | 0.82 | 0.92 (0.90-0.94) | 600 |
| [45] | Pfizer | non-Delta | Symptomatic | 2.37 | 0.93 (0.88-0.95) | 210 |
| [46] | Astrazeneca | Delta | All infections | 0.19 | 0.67 (0.62-0.71) | 420 |
| [46] | Astrazeneca | non-Delta | All infections | 0.54 | 0.79 (0.56-0.90) | 25 |
| [46] | Convalescent | Delta | All infections | 0.35 | 0.72 (0.58-0.82) | 53 |
| [46] | Convalescent | non-Delta | All infections | 1 | 0.60 (0.50-0.68) | 125 |
| [46] | Pfizer | Delta | All infections | 0.82 | 0.80 (0.77-0.83) | 780 |
| [46] | Pfizer | non-Delta | All infections | 2.37 | 0.78 (0.68-0.84) | 100 |
| [47] | Astrazeneca | non-Delta | All infections | 0.54 | 0.79 (0.65-0.88) | 50 |
| [47] | Pfizer | non-Delta | All infections | 2.37 | 0.80 (0.73-0.85) | 185 |
| [48] | Convalescent | Delta | Symptomatic | 0.35 | 0.93 (0.87-0.96) | 169 |
| [49] | Moderna | Delta | Symptomatic | 1.44 | 0.86 (0.71-0.94) | 42 |
| [49] | Pfizer | Delta | Symptomatic | 0.82 | 0.56 (0.41-0.67) | 64 |
| [50] | Astrazeneca | non-Delta | All infections | 0.54 | 0.56 (0.41-0.67) | 63 |
| [51] | Astrazeneca | non-Delta | Symptomatic | 0.54 | 0.78 (0.70-0.84) | 150 |
| [51] | Pfizer | non-Delta | Symptomatic | 2.37 | 0.93 (0.86-0.97) | 100 |
| | | | | | | |

Table S2. Ratios of neutralizing antibody titers to Delta or non-Delta variants of SARS-CoV-2 from vaccination or infection SARS-CoV-2.

| Reference | non-Delta variant | Sample type | Ratio non-Delta to Delta |
|-----------|-------------------|-----------------|--------------------------|
| [4] | D614G | Pfizer-BioNtech | 4.5 |
| [4] | D614G | Astrazeneca | 4.5 |
| [22] | Wild Type | Pfizer-BioNtech | 1.28 |
| [5] | Wuhan | Pfizer-BioNtech | 11.30 |
| [5] | Wuhan | Astrazeneca | 4.01 |
| [52] | Wild Type | Pfizer-BioNtech | 2.1 |
| [52] | Wild Type | Astrazeneca | 2.1 |
| [53] | Wild Type | Pfizer-BioNtech | 5.8 |

| [54] | Wild Type | Astrazeneca | 8.0 |
|------|-----------|------------------|------|
| [7] | Wild Type | Pfizer-BioNtech | 1.18 |
| [7] | Wild Type | Astrazeneca | 1.22 |
| [6] | D614G | Pfizer-BioNtech | 2.0 |
| [6] | D614G | Astrazeneca | 5.0 |
| [4] | D614G | Convalescent | 2.1 |
| [6] | D614G | Convalescent | 2.1 |
| | | Estimated ratio* | 2.88 |

Table S3. Logistic regression analysis of protection (vaccine efficacy or effectiveness or protection from previous infection) with the log-transformed ratio of neutralizing antibody titers (NAT-Ratio) relative to convalescent sera, with an interaction with four groups for variant (Delta and non-Delta) and endpoint (symptomatic cases or all infections) as shown in Figure 1. Delta – infection was the reference level.

| Predictor | Estimate | SE | Z-value | P-value |
|--|----------|-------|----------------|----------|
| Intercept | 1.47 | 0.10 | 14.49 | < 0.0001 |
| log ₂ (NAT-Ratio) | 0.32 | 0.064 | 4.97 | < 0.0001 |
| non-Delta – symptomatic | 0.10 | 0.11 | 0.87 | 0.39 |
| non-Delta – infection | -0.41 | 0.13 | -3.00 | 0.0027 |
| Delta – symptomatic | 0.77 | 0.13 | 5.79 | < 0.0001 |
| log ₂ (NAT-Ratio):non-Delta - symptomatic | 0.27 | 0.076 | 3.59 | 0.00034 |
| log2(NAT-Ratio):non-Delta - infection | -0.035 | 0.12 | -0.29 | 0.77 |
| log2(NAT-Ratio):Delta - symptomatic | 0.22 | 0.089 | 2.50 | 0.012 |

Table S4. Analysis of waning rates of neutralizing antibodies for two vaccines (Pfizer-BioNtech and Moderna) and infection-derived immunity. The best fitting model by AIC was Antibody titer = $(c_0+c_7*Infection)*e^{(c_1*Day+c_3*Day*Moderna+c_4*Infection*Day)}+c_2+c_6*Infection$, where Pfizer-BioNtech was the reference level. There was no support for Moderna having a different asymptote than Pfizer (P-values>0.45 for coefficients similar to c_7 and c_6).

| Coefficient | Estimate | SE | t-value | P-value |
|----------------|----------|--------|---------|----------|
| C 0 | 0.90 | 0.032 | 28.42 | < 0.0001 |
| c ₁ | -0.023 | 0.0024 | -9.77 | < 0.0001 |
| C2 | 0.12 | 0.026 | 4.49 | 0.0012 |
| C 3 | 0.013 | 0.0021 | 5.96 | 0.0001 |
| C4 | 0.0092 | 0.0044 | 2.11 | 0.061 |
| C6 | 0.18 | 0.044 | 4.13 | 0.0020 |
| C 7 | -0.20 | 0.061 | -3.21 | 0.0094 |

^{*}There was no significant difference in the ratios among sample types (either vaccines or convalescent sera): mixed effects model of log-transformed ratio with Sample Type as a fixed effect and study as a random effect; likelihood ratio $\chi^2(df=2) = 2.6$; P = 0.26.

Table S5. Fraction of the population in each group for the five scenarios in Figure 3, using the case ratios in vaccinated and unvaccinated individuals and the timing of vaccinations and infections derived from COVID-19 deaths and vaccinations as of October 15, 2021 in the USA (Figures S2-S4).

| Scenario | Fraction vaccinated and infected | Fraction vaccinated and not infected | Fraction unvaccinated and infected | Fraction fully susceptible ((1-f _{PU})*f _U) |
|--------------|--|--------------------------------------|---|---|
| DO 27 560/ | $(\mathbf{f}_{PV}^*\mathbf{f}_{V})$ | $((1-f_{PV})*f_{V})$ | $(\mathbf{f}_{\mathrm{PU}}^{*}\mathbf{f}_{\mathrm{U}})$ | 0.14 |
| R0=3.7; 56% | 0.26 | 0.30 | 0.30 | 0.14 |
| vacc., 56.4% | | | | |
| prev. inf. | | | | |
| R0=3.7; 60% | 0.0012 | 0.60 | 0.004 | 0.40 |
| vacc., 0.52% | | | | |
| prev. inf. | | | | |
| R0=3.7; 75% | 0.18 | 0.57 | 0.11 | 0.14 |
| vacc., 28.2% | | | | |
| prev. inf | | | | |
| R0=7; 100% | 0.56 | 0.44 | 0 | 0 |
| vacc., 56.4% | | | | |
| prev. inf. | | | | |
| R0=7; 56% | 0.26 | 0.30 | 0.30 | 0.14 |
| vacc., 56.4% | | | | |
| prev. inf. | | | | |

Table S6. Estimated protection (and 95% CI) against infection (VE_I) and transmission (VE_T) given waning of vaccine and infection derived immunity, as of October 15, 2021 in the USA, using case ratios in vaccinated and unvaccinated individuals and the timing of vaccinations and infections derived from COVID-19 deaths and vaccinations (Figures S2-S4). These estimates are derived from the rates of waning of neutralizing antibody titers (Figure 2; Table S4) and the relationship between neutralizing antibody titers and protection against infection for Delta (Figure 1; Table S3) and transmission given infection (Figure S1).

| Endpoint | Estimate with waning (95% CI) |
|--|-------------------------------|
| VE _{IP} (infected and unvaccinated) | 0.627 (0.565-0.685) |
| VE _{TP} (infected and unvaccinated) | 0.125 (0.086-0.181) |
| VE _{IV} (vaccinated and uninfected) | 0.675 (0.637-0.712) |
| VE _{TV} (vaccinated and uninfected) | 0.186 (0.152-0.226) |
| VE _{IH} (vaccinated and infected) | 0.827 (0.792-0.857) |
| VE _{TH} (vaccinated and infected) | 0.464 (0.341-0.583) |
| VE _{IB} (boosted with third dose) | 0.873 (0.828-0.907) |

| VE _{TB} (boosted with third dose) | 0.608 (0.428-0.764) |
|--|----------------------|
| (ZIB (COOSCO (IIII IIII COSC) | 0.000 (0.1.20 0.701) |




Figure S1. Protection against transmission given infection plotted against the ratio of neutralizing antibody titers relative to convalescent sera from infection with SARS-CoV-2 for Astrazeneca (left filled triangle) and Pfizer (right filled triangle) [21]. The raw data is in Table S1 – Transmission endpoint. Open squares show the estimated protection with waning (left open square) and boosting (right open square). The fitted model is: logit(Protection) = $-0.336 (\pm 0.225) + 0.549 (\pm 0.124) * log2(neut. antibody ratio); P<0.0001.$




Figure S2. Number of people fully vaccinated in the USA [26].




Figure S3. COVID-19 cases, deaths, and infections inferred from deaths in the USA [23].




Figure S4. Ratio of COVID-19 cases in unvaccinated individuals relative to vaccinated individuals in the USA in 2021 [28].